Research Progress on Neuraminidase Inhibitors Against Influenza Virus
Influenza is an acute upper respiratory tract infectious disease caused by influenza viruses that seriously endangers human health.
September 10, 2025
by Xiaonisha
Made-in-China New Drugs: The Game and Breakthrough in the Over - 4 - Billion Market
Profiles 16 China-made blockbuster drugs exceeding ¥1B sales, highlighting intense PD-1 competition, EGFR tech innovation, and bispecific antibody/non-oncology surge.
September 5, 2025
by Lezhi
Research Progress on 5-Lipoxygenase and Its Inhibitors
Lipoxygenases are a class of non-heme iron-containing dioxygenases present in tissues and cells of both animals and plants.
September 5, 2025
by Xiaonisha
Research Progress on Nrf2 Activators Based on Natural Products and Their Derivatives (Part I)
The Keap1-Nrf2-ARE signaling pathway is one of the critical mechanisms for cellular defense against oxidative stress damage.
August 22, 2025
by Xiaonisha
The Global Alpha-Glucosidase Inhibitor Market: Trends and Prospects
Alpha-glucosidase inhibitors are used for type 2 diabetes. This article analyzes their market, including growth, segments, and challenges.
March 18, 2025
by David Orchard-Webb
Advances in Research on New Therapeutic Drugs for Myelodysplastic Syndromes (Part one)
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic malignancies characterized by defective normal hematopoiesis leading to a reduction in blood cells, with a risk of transformation into acute myeloid leukemia.
July 9, 2024
by Xiaomichong
A comprehensive review of the currently marketed ADC drugs: the industry maintains high prosperity
Antibody-drug conjugates (ADCs) are a class of drugs composed of antibodies targeting tumor antigens and a variable number of small molecule toxins linked through connectors.
November 7, 2023
by WND
Drug Marketing in China and Worldwide (August)(2023)
The official website shows that the drugs developed by major companies have been declared for marketing.
September 1, 2023
by PharmaSources
Are the Fourth Generation EGFR Inhibitors the Next Wealth Creation Myth?
Junshi Biosciences WJ13404 Has Been Submitted for Clinical Application
April 18, 2022
by PharmaSources/Yefenghong
Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients
Ascletis Pharma Inc. (HKEX: 1672) today announces that Shanghai Public Health Clinical Center initiated functional cure study of anti-PD-L1 antibody ASC22 (Envafolimab) in combination with Chidamide...
February 15, 2022
by prnasia
FLIP sync: Collaboration for inhibitors and cancer treatments
Ipsen and Domainex collaboration will provide an exclusive licence to develop innovative inhibitors and pioneering cancer treatments.
January 26, 2022
by pharmatimes
Applied Pharmaceutical Science Inc. Announces FDA Approval of Investigational New Drug Application for APS03118, a Next generation RET Original New Drug for Unlimited Cancers
Applied Pharmaceutical Science, Inc. ("APS" or "the Company"), has recently announced the Investigational New Drug (IND) application for its self-developed breakthrough new drug APS03118...
January 24, 2022
by prnasia